A5010406195- Estrogen and related hormone effects
- Cytokine Signaling Pathways and Interactions
- Endometriosis Research and Treatment
- Retinoids in leukemia and cellular processes
- Reproductive System and Pregnancy
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Uterine Myomas and Treatments
- Cancer Cells and Metastasis
- Cancer, Hypoxia, and Metabolism
- Endometrial and Cervical Cancer Treatments
- Bioactive Compounds and Antitumor Agents
- Immune cells in cancer
- RNA Research and Splicing
- Breast Cancer Treatment Studies
- Curcumin's Biomedical Applications
- Ubiquitin and proteasome pathways
- Cancer-related molecular mechanisms research
- Nigella sativa pharmacological applications
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Pharmacological Effects of Medicinal Plants
- Fibroblast Growth Factor Research
- Ferroptosis and cancer prognosis
- Pregnancy and Medication Impact
Evestra (United States)
2015-2025
The University of Texas Health Science Center at San Antonio
2010-2025
The University of Texas at San Antonio
2025
The University of Texas Health Science Center at Houston
2008-2021
Texas Biomedical Research Institute
2011-2015
Kannur University
2013
The University of Texas MD Anderson Cancer Center
2011
Weizmann Institute of Science
2011
Beijing Obstetrics and Gynecology Hospital
2007
// Hari Singhal 1 , Marianne E. Greene 3 Allison L. Zarnke Muriel Laine Rose Al Abosy Ya-Fang Chang Anna G. Dembo Kelly Schoenfelt Raga Vadhi 2 Xintao Qiu Prakash Rao Bindu Santhamma 4 Hareesh B. Nair Klaus J. Nickisch Henry W. Long Lev Becker Myles Brown 1,2 and Geoffrey Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Center for Functional Epigenetics, Ben May Research, University Chicago, Illinois, Evestra Inc., San Antonio, Texas, Correspondence...
Background: Inflammatory breast cancer (IBC) is a rare subtype of accounting for 7% cancer-related fatalities. There an urgent need to develop new targeted treatments IBC. The progression IBC has been associated with alterations in growth factor and cytokine signaling; however, the function LIF (leukemia inhibitory factor)/LIFR receptor) pathway remains unknown. This study evaluated role LIFR signaling tested efficacy inhibitor EC359 treating Methods: utility using inhibition as treatment...
Epidemiologic studies have implicated estrogenic exposure as well human papilloma virus (HPV) infection in cervical carcinogenesis, and some suggested that estrogen HPV may play synergistic roles tumorigenesis. In this study, we report a novel finding approximately 35% of carcinomas tested (n = 19) express aromatase, the enzyme responsible for converting androgen to estrogen, rate-limiting final step biosynthesis. On other hand, no aromatase expression was detected precancerous 42) or normal...
Abstract Cervical cancer is the third most common gynecologic in United States. The presence and possible involvement of several cytokines have been studied cervical cancer; however, very little data, if any, are available on whether tumors responsive to stimulation by macrophage colony-stimulating factor-1 (CSF-1). Given c-fms its ligand CSF-1 cancers, such as that uterus ovaries, we examined expression tumor (n = 17) normal cervix 8) samples. data show significantly higher carcinomas...
Transforming growth factor beta 1 (TGF-beta1) levels are increased in the peritoneal fluid of endometriosis patients, and endometrial cells express TGF-beta signaling components; however, little is known regarding role endometriosis. Our objective was to examine effects TGF-beta1 on (i) expression macrophage colony-stimulating receptor encoded by c-fms gene, (ii) transmesothelial invasiveness cells, (iii) cellular proliferation (iv) attachment mesothelial (PMCs). Effects mRNA were determined...
Triple‑negative breast cancer (TNBC) lacks the expressions of estrogen receptor‑α, progesterone receptor and human epidermal growth factor receptor‑2. The treatment options for TNBC include anthracyclin/taxol based conventional chemotherapy small molecular inhibitor targeted therapy. However, therapeutic efficacy is limited by systemic toxicity acquired tumor resistance; identification less toxic testable alternatives urgently required. Non‑toxic nutritional herbs are commonly used in...
A number of recent studies have suggested that the colony-stimulating factor (CSF-1) and its receptor c-fms may be involved in development mammary glands during lactation breast cancer. To study role CSF-1 or initiation tumorigenesis, we generated two independent lines transgenic mice overexpress either under control mouse tumor virus promoter. Mammary virgin show increased ductal branching, hyperplasia, dysplasia, other preneoplastic changes, which are indicative cellular proliferation....
Abstract In situ estrogen synthesis is implicated in tumor cell proliferation through autocrine or paracrine mechanisms especially postmenopausal women. Several recent studies demonstrated activity of aromatase, an enzyme that plays a critical role breast tumors. Proline-, glutamic acid-, and leucine-rich protein-1 (PELP1/MNAR) receptor (ER) coregulator, its expression deregulated this study, we examined whether PELP1 promotes growth by promoting local using cancer cells (MCF7) stably...
Mutation in the BRAF gene (BRAFV600E) exists nearly 70% of human melanomas. Targeted therapy against BRAFV600E kinase using a recently identified RAF-selective inhibitor, PLX4032, has been successful early clinical trials. However, patients with normal allele (wild-type), PLX4032 is protumorigenic. This conundrum identifies unmet need for novel therapeutic agents to target that are not counterproductive. We have gossypin, pentahydroxy flavone, as potent antimelanoma agent. Gossypin inhibited...
Abstract Introduction Proteasome inhibition provides an attractive approach to cancer therapy and may have application in the treatment of breast cancer. However, results recent clinical trials evaluate effect proteasome inhibitor Bortezomib (Velcade ® , also called PS-341) metastatic patients shown limited activity when used as a single agent. This underscores need find new more efficacious inhibitors. In this study, we efficacy novel BU-32 (NSC D750499-S) using vitro vivo models. Methods...
Letrozole is a potent aromatase inhibitor and superior to other defined selective estrogen receptor modulators such as tamoxifen in treating hormone-responsive postmenopausal breast cancer patients. Patients who receive this drug may become insensitive the effects of deprivation induced by letrozole. has known side on bone metabolism due systemic ablation production. The purpose study was examine therapeutic efficacy hyaluronic acid-bound letrozole nanoparticles (HA-Letr-NPs) restoring...
Abstract Study Rationale: The triple negative breast cancer (TNBC) lacks the expression of hormone and growth factor receptors responds only to anthracycline/taxol-based conventional chemotherapy. Major therapeutic limitations include systemic toxicity acquired resistance chemo-therapeutics. Relatively non-toxic nutritional herbs from traditional Chinese medicine (TCM) may represent testable alternatives against TNBC. These effectively target multiple signaling pathways (Yang et al: J....
Triple negative breast cancer (TNBC) is characterized by the absence of hormones and growth factor receptors. It typically responsive to anthracycline/taxol‑based conventional chemotherapy. However, major therapeutic limitations include systemic toxicity acquired resistance chemotherapeutics. To combat this, nutritional herbs from traditional Chinese medicine (TCM) with limited reported may represent treatment alternatives for TNBC. Such can effectively target multiple signaling pathways in...